Prevalence of Emerging Treatment-induced Mutations in Metastatic ER-positive Breast Cancer.

NCT06417801 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2026-03-19

No results posted yet for this study

Summary

Observational study on prevalence of emerging ESR1 mutations in liquid biopsy in two cohorts of patients with breast cancer (with and without prior therapies in metastatic setting) in comparison with patient's baseline ESR1 mutation status as defined by tissue profiling.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Rodrigo Dienstmann · Oncoclínicas

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-17
Primary Completion
2027-12-30
Completion
2027-12-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06417801 on ClinicalTrials.gov